Member Info for Steadydanny

Fall Healthcare Life Sciences & MedTech SummitSeptember 20-23, 2021Virtual

Please Save-the-Date for our virtual Fall Healthcare Life Sciences & MedTech Summit from September 20-23, 2021.

September 20-22 will feature presentations and 1on1 meetings in a virtual format with a select group of public companies in the Healthcare Life Sciences and MedTech arena. Thursday, September 23 will be our Private Company Day within the Summit and will feature a select group of emerging biotechnology and life science private companies. Investors will have the opportunity to meet virtually with management teams to discuss in detail key therapeutic programs in development and recent corporate updates.

Contact your Oppenheimer sales representative or Financial Professional to RSVP. You may also email opcoconferences@opco.com to register.

Keep watching 737 and its ipr holder
Love the private company day on 23rd bit and don't forget the fireside chat on the 28th.....
Tick tock tick tock ...

Hi WIP.
Extract from out trading update 19th August 2021 re 737
The Company continues to monitor licence holder Sierra Oncology's activities as it explores options to fund the future development of SRA737. Sareum continues to believe that the amended licensing agreement between Sierra and CRT Pioneer Fund (CPF) could expedite the advancement of the SRA737 programme in a timely manner.
I'm not sure about the ammendment but average funding is £600k. And Sierra are financially very secure. With a $34m option.
Maybe I have misread (happy to be put in check) but I would have thought that the CPF mention might see transatlantic cooperation with progression in something others have realised they are behind the curve so we have a free reign?
Anyways we are down 1.5% over a month despite shenanigans and up over 300 % in 6 months.
Subscriptions in place. Warrants part taken and more available.
I think Thoth is in a good place. If he's happy I'm happy. I just hope no one has told him that the CO2 issue (being sorted) could affect wotsit production.
Regards Steadydanny

Le Major. Personally I'd prefer Grenada.
Re FOMO the communication silence is deafening. I like the term no news is good news. Or calm before the storm (in a good 'cytokine storm' way.
2 hrs until Sierra partake in a conference.....our ceo did say he did like the new appointment they made and his review of pipeline products ....so maybe a hint? But who knows. But reading other pharma boards and RNSs the treatment option seems to be the 'hot topic'.
And AZ would have done dd here re Sierra hook up. They have been busy busy busy!
I've seen this 'doldrums' scenario a few times as I'm sure others have. Too many positives since June (albeit silence since 19th August...we were not the only company to go quiet after an update on that date) for this not to have something simmering.
I reckon the ducks are lined up, a few tweaks here and there, passengers advised to turn phones to airplane mode, buckle seats and in-flight entertainment will commence after take off.
So many opportunities to the multiple destination points but we have our boarding passes.
Best wishes to all.

2pm ET. Maybe a snippet re 737......final one a week today 3 days prior to Q4.....

Let's see how that 'savvy' company discusses its expert timing in selling some He1 shares at top price to fund its own new development just prior to the sp sinking.
Popcorn at the ready

I think it's about income. Promised income. Not hearsay. This is going to come onto careful investors radars soon. The last updates are akin to the Edison report at Sareum re advising HNWIs of savvy investments.
For once I think I got in early!? But we know the way it plays out. Bide their time before it's too obvious.
However, I will bet a pound to a penny this news is a dry run prior to Q4. I expect a couple more updates this month.
Imo. Etc

But reading the updates we are imo due an 8% rise minimum. Also some of the sells are buys.

Ciz just had an EQS. 345PM

Meant EQS but still further communication and positive updates.

Shame not to really....the news keeps coming

Less shares in ciz. But nevertheless very encouraging for both.

Many thanks SOG. Fingers crossed for next week.
Pretty engrossed in watching live YouTube of La Palma. Not good.

Hi Mafuta. Appreciate your response. I was just thinking the dry powder nebuliser could be distributed deeper into the respiratory system due to being put on a ventilator.
Anyways, interesting times .
Best regards Steadydanny
Sierra has another conference this week (and the fireside chat after just prior to end of September)and Q4 updates from us surely re forthcoming trials re money at bank and how it will be spent incoming ......

Following on from your post SOG. I appreciate treatments have been discussed. Pill or via a nebuliser. I note GSK who produce asthma inhalers are noting its impact on the environment. I further note they actually produce a 'dry powder' inhaler which is common in Scandinavia but not UK or US.
I then bring into discussion il 6 which I find rather intriguing. This is an extract from The Lancet 26th June 2021. Just putting it out there but is it possible nebuliser administration of a treatment might be something we add value to re covid treatment?

Currently, the guideline strongly recommends the use of anticoagulation in all patients admitted to hospital with COVID-19, and strongly recommends the use of systemic corticosteroids in all patients admitted to hospital who require supplementary oxygen or ventilatory support. Conditional recommendations were made for IL-6 receptor antagonist monoclonal antibody therapies only for patients in hospital with COVID-19 requiring oxygen or ventilatory support who have received corticosteroids, and for use of high flow nasal oxygen or continuous positive airway pressure in patients with hypoxaemic respiratory failure. Currently the guidelines strongly recommend against the use of hydroxychloroquine and lopinavir–ritonavir, and makes conditional recommendations against the use of azithromycin, colchicine, interferon beta, and remdesivir (eg, the guideline recommends not to offer remdesivir to patients in hospital with COVID-19 who require invasive mechanical ventilation, but make no recommendations regarding when remdesivir could be used).
Just a further point for perusal re Sareums treasure chest.
Regards Steadydanny

I agree. Fascinating company and its heritage and past affiliations. I'm just starting research on Takeda and (takeover of) Millenium Pharmaceutical and BODs previous positions and patent application re Japan and China.....and Milleniums statement re US partners.
It's like a Terry's chocolate orange (other confectionairies are available) , once you tap it you can't stop. It goes back some time. Hence some do DYOR over 6 months. Longer gives better information.
I appreciate I look outside of the normal rhetoric of some posters but I like to pursue avenues of previous appointments and said companies corporate objectives...and trading statements.
If a company was due an offer......

Following on from last night and my point re REGN COV2 and monoclonal antibodies.
I note from Cancer research UK news release 28 July 2011 that Blink therapeutics was formed 13 June 2011.
...Blink will develop the novel platform to generate therapeutic and diagnostic monoclonal antibodies towards clinically relevant targets.
It goes on re end of 2005 Astra Zeneca acquired KUDOS for £121m....to progress innovative therapies relating to DNA repair. ( those used to my rambles know I go on about dna damage re rna dna crossover and tyrosine being replaced by uracil leaving toxic cytosine to build up causing cytokine storms)
Also Plramed acquired by Roche in April 2000 ( they are REGN COV2!)
Back to Blink Therapeutics. Sareum RNS re appointment of Michael Owen update on forgetting to initially add his time at Blink Therapeutics
Mon, 29th Jul 2019 16:29

RNS Number : 0933H

Sareum Holdings PLC

29 July 2019

 

(AIM: SAR)

29 July 2019

 

Sareum Holdings plc

("Sareum" or "the Company")

Additional disclosure concerning Michael Owen

 

Sareum Holdings PLC, the specialist small molecule drug development business, announced on 13 November 2018 the appointment of Michael Owen as a Non-Executive Director of the Company.

It has come to Sareum's attention that whilst his former directorship of BliNK Biomedical SAS ("BliNK") was detailed in that announcement, his former directorship of BliNK's subsidiary Blink Therapeutics Limited during the five years prior to that announcement should also have been included.
Maybe we are not so removed from the rollout next week as thought.
Best regards Steadydanny
Also SOG Many thanks for the chronology of 1802. Great reading.

 

SOG. Very interesting. I thought I had a fair understanding of sareum. I'm definitely swotting up further this weekend. It is interesting how world politics and protocols seem to have a part dovetail into our research.
Very best regards and very many thanks Steady.

SOG.
Greatly appreciate your response and your posts. I Have been a bit quiet here for a couple reasons. But hey ho.
Excuse my naivety but if you could (I appreciate you have better things to do) advise my further thoughts given your response.
1802 is a tweak of 1801 I believe. We upped our patent application in US. When I read large companies feeds I often look at what they are withholding.
Roche advised partnering in US. Regeneron or something. And others. But they would need to finance their own further trials. So maybe could it be not a drip? And re US and tommiblium ( I can never spell it) and Sierra and they advised they were able to access $33m if required within a time frame for further trials. Then we have our own subscription raise in blighty. Then our ceo mentioning the Patent update to cover us in US to further protect our ipr.
And the 19th August could just be a coincidence re Rothe and Sareum.
I'm not great at being succinct but am I looking at clouds in the sky and seeing patterns that are only in ones mind?
I am a bit of a nimbus.
Once again many thanks SOG and i will scuttle off and do more research. I keep reading this bb and enjoy the genuine posters.
Best regards Steadydanny

Extract 30th July RNS

The patent (US Patent Application no. 16/343,639) will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase. This programme is in preclinical development.

The Company expects that the patent will be granted within three months, subject to certain formalities being completed.

Sareum's CSO, Dr John Reader, commented:

"The granting of this patent in the US will provide a further layer of protection around SDC-1802 following the granting of patents protecting the molecule in the US and other major markets in recent years. These patents are important to enhancing the value of the programme as part of our discussions with potential partners."

Should say 2/3 trials...sorry just a bit excited...just ties in with Q4 and 2022.
OK I will take a breather and hope I haven't made a duck of myself.